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Abstract Dopa-responsive dystonia (DRD) has a classic
presentation of childhood or adolescent-onset dystonia,
mild parkinsonism, marked diurnal fluctuations, improve-
ment with sleep or rest, and a dramatic and sustained
response to low doses of L-dopa without motor fluctuations
or dyskinesias. However, there have been many papers on
patients with a wide range of features, which report them
as DRD mainly because they had dystonic syndromes with
L-dopa responsiveness. Many mutations in the dopaminer-
gic system have been found as molecular genetic defects.
Therefore, the clinical and genetic spectra of DRD are
unclear, which lead to difficulties in diagnostic work-ups
and planning treatments. We propose the concept of DRD
and DRD-plus to clarify the confusion in this area and to
help understand the pathophysiology and clinical features,
which will help in guiding diagnostic investigations and
planning treatments. We critically reviewed the literature
on atypical cases and discussed the limitations of the gene
study.
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Introduction
Dopa-responsive dystonia (DRD) was first recognized by
Segawa et al. in 1972 [1]. They described 2 female cousins
who showed gait disturbance with dystonia at ages 4 and 6.5.
The symptoms were relatively mild in the morning and be-
came severe in the late afternoon or evening. The 2 patients
improved markedly by L-dopa treatment.
In fact, Segawa’s report was not the first description for
DRD. In 1947, Beck reported an 8.5-year old girl who had
showed “kicking up her left heel when walking.” She had
generalized dystonia, tremor, masked face, and difficulty in
gait. Her paternal uncle had similar problems with walking at
age 8. She was reported as “a typical case of dystonia
musculorum deformans” [2]. Several years later, the same
patient was re-assessed by Corner [3]. He noted that her
symptoms waxed and waned, and trihexyphenidyl improved
her performance remarkably. These features are in good agree-
ment with what is now known as DRD.
There have been many reports with similar clinical features
under different diagnostic terms [2, 4–13]. The term “DRD”
was suggested by Nygaard et al. [12, 14], and has generally
been accepted. However, there have been many reports under
the name DRD with atypical or “incompatible” features as
will be discussed below, leading to confusion as to what DRD
exactly is. Therefore, in 1998 we proposed a definition for
DRD and DRD-plus as a clinical syndrome based on all the
information at that time [15, 16]. We believe that this concept
clarifies much of the confusion as to the clinical features and
helps with the diagnostic work-up and treatment planning.
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Because the misuse of the term DRD continues, we critically
reviewed the literature and recapitulated the concept.
Clinical Presentation of Classical DRD
Typical clinical features of DRD are childhood or adolescent-
onset dystonia sometimes associated with mild parkinsonism,
marked diurnal fluctuations, and improvement with sleep or
rest, and a dramatic and sustained response to low doses of L-
dopa without motor fluctuations or dyskinesias as the hall-
mark of the disease [17]. Diurnal fluctuations are not specific
to DRD, because they could arise in other neurologic disor-
ders [18•, 19, 20]. A marked and sustained response to L-dopa
without motor fluctuations or dyskinesias is the most impor-
tant feature that enables clinicians to distinguish DRD from
other dystonias and parkinsonism.
There are many reports of atypical presentations and vari-
able onset age from early infancy to late adulthood. Early
infantile presentations mimic cerebral palsy [21]. Adult onset
presentations include focal dystonia and parkinsonism [22].
Psychomotor retardation, convulsion, systemic symptoms,
and cerebellar dysfunction have also been reported [23, 24].
Even though an excellent response to L-dopa is the hallmark
of DRD and delayed treatment for decades has resulted in
complete resolution of symptoms [25], an incomplete re-
sponse for action dystonia has been reported [26]. An autoso-
mal dominant heterozygous mutation in the GTP
cyclohydrolase I (GCH-1) gene resulting in biopterin deficien-
cy, which is the cofactor for tyrosine hydroxylase (TH) and
dopamine deficiency is the most classic molecular pathophys-
iology [27].
Definition of DRD and DRD-Plus
Because of clinical and genetic heterogeneity, there may be
confusion as to what DRD is. To prove this point, there have
been reports under the name of DRD, which do not fit into the
known pathophysiology of DRD, adding confusion in this
area. Therefore, we previously proposed that DRD be defined
as a syndrome of selective nigrostriatal dopamine deficiency
caused by genetic defects in the dopamine synthetic pathway
without nigral cell loss [16]. It covers all the typical and
atypical presentations of DRD with proven mutations, and
allows for a diagnosis of DRD without genetic confirmation.
We further proposed the term "DRD-plus", defined as
inherited disorders, in dopamine metabolism, which have
features of DRD and additional features that are not seen in
DRD [16]. We suggested that this concept is useful in
allowing for a diagnosis of DRD without requiring proof of
genemutations, which is not practical and may not be possible
in some cases, and in the systematic planning of the clinical
and laboratory evaluation of patients who have some features
of DRD but who also have features that have not been report-
ed or are unexpected in DRD. The phenotypes of DRD-plus
are as follows: (1) earlier onset than DRD such as neonatal
onset, (2) more severe motor phenotypes such as poor suck-
ing, swallowing difficulties, severe hypotonia, and (3)
nonmotor features (extra-nigrostriatal dopaminergic
dysfunctions) such as convulsions (grand mal or myoclonic
attacks), psychomotor retardation, mental retardation, drows-
iness, irritability, recurrent hyperthermia without infections,
and ptosis.
We then predicted that the dichotomy might not always be
rigid concerning the causative mutation because the same
gene mutation may present as DRD or DRD-plus depending
on the degree of the enzymatic deficiency. In the following
review, we will emphasize that these heterogeneous groups
can be divided into DRD in the strict sense and DRD-plus.
This division will help to understand the pathophysiology,
clinical features, diagnostic investigation and treatment
planning.
Pathogenesis
Tetrahydrobiopterin (BH4) is a cofactor of TH. TH makes
dopamine from tyrosine. GCH-1 takes the initial step in the
synthesis of BH4. The other steps in BH4 metabolism are 6-
Pyruvoyltetrahydropterin synthase (6-PPH4 synthase),
sepiapterin reductase (SR), and dihydropteridine reductase
(DHPR) (Fig. 1). The defect in GCH-1 activity causes de-
creased dopamine synthesis, and a low neopterin level [28,
29]. On the other hand, the deficiency of 6-PPH4 synthase,
SR, or DHPR does not seem to affect the neopterin level.
DRD patients do not show hyperphenylalaninemia (HPA),
althoughBH4 is also a cofactor for phenylalanine hydroxylase
[30]. Nigrostriatal dopaminergic neurons appear to be more
vulnerable to the BH4-deficient state than that of liver cells. It
may be because BH4 stimulates TH gene expression and,
thereby, plays a role in the control of the steady-state levels
of the protein for which it acts as a cofactor [31]. Another
possibility is that GCH-1 in the brain may be differentially
regulated from that in the liver. GCH-1 activity in various
tissues might depend on different degrees of expression of the
normal and mutant mRNAs [29]. It is of interest that brain
biopterin loss (−82 %) in asymptomatic carriers was similar
with that reported in DRD patients (−84 %), but TH protein
and dopamine levels (−52 % and −44 %, respectively) were
less severe (DRD patients, −97 % and −88 %, respectively).
The results mean that TH protein loss may affect critically the
clinical symptoms of DRD [32].
In stark contrast to Parkinson’s disease (PD), pathologic
examination shows no degenerative nigral cell loss even
though there is a decrease of melanin containing neurons in
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the pars compacta of the substantia nigra (SN) [33]. The
pathologic findings of DRD are supported by fluorodopa
positron emission tomography (PET) and dopamine transport-
er imaging. It presents normal uptake patterns in DRD [15,
34–36].
Our definition of DRD as a selective nigrostriatal dopamine
deficiency caused by genetic defects in the dopamine synthet-
ic pathway without nigral cell loss means that DRD is not a
neurodegenerative disorder, but a biochemical disorder which





BH4 is also the cofactor for phenylalanine hydroxylase.
Therefore, a defect in BH4 can result in HPA as in cases with
autosomal-recessive homozygous or compound heterozygous
mutations [24, 37]. Autosomal-dominant GCH-1 deficiency
has a selective GCH-1 defect in the brain and not in the liver,
thus, does not present with HPA. However, hepatic
phenylalanine hydroxylase with partial BH4 deficiency is
not able to convert phenylalanine to tyrosine at a normal rate
under loading conditions. Profiles of plasma phenylalanine
and tyrosine and phenylalanine/tyrosine ratios are abnormal
after oral phenylalanine loading [38]. Although this test can
differentiate between asymptomatic and symptomatic gene
carriers, false-positive, and false-negative results are possible.
In fact, heterozygote carriers for phenylketonuria show the
same abnormal phenylalanine and tyrosine profiles [39],
whereas a small number of genetically confirmed DRD sub-
jects showed no abnormalities with this test [40]. The addi-
tional measurement of plasma total biopterin improves the
sensitivity [38]. The phenylalanine loading test could help
with a differential diagnosis between GCH-1 deficiency and
TH deficiency. Phenylalanine blood levels remain increased in
GCH-1 deficiency, and are normal in TH deficiency.
Neopterin and Biopterin
The phenylalanine loading test is not helpful in distinguishing
GCH-1 deficiency from SR deficiency, whereas neopterin and
biopterin measurements are useful in discriminating between
GCH-1 deficiency and SR deficiency. Neopterin is a catabolic
product, which is formed in the first stage of the BH4 synthetic
pathway by the GCH-1 enzyme (Fig. 1). Biopterin is a
Fig. 1 Dopamine biosynthetic
pathway
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degradation product from BH4 or dihydrobiopterin (BH2),
and is found in the last part of the BH4 biosynthesis pathway.
Therefore, GCH-1 deficiency shows decreased neopterin and
biopterin levels in CSF. In contrast, the CSF neopterin level in
SR deficiency is normal while the CSF biopterin level is high
[30].
Neopterin in CSF is decreased to less than 20 % of normal
values in DRD, which is lower than the values for PD and
other dopa-nonresponsive basal ganglia diseases [41]. CSF
neopterin in asymptomatic carriers is 30 %–40 % of normal
values [42].
Enzyme Assay (Measurement of GCH-1)
Enzymatic diagnosis of DRD is limited by the fact that the
enzyme GCH-1 is not expressed in blood cells and fibroblasts.
An assay in phytohemagglutinin-stimulated mononuclear
blood cells shows reduced activity in heterozygous and ho-
mozygous GCH-1 patients, and in DRD patients [43, 44]. The
activity of GCH-1 in mononuclear blood cells is decreased to
less than 20 % of normal levels in patients and to 30 %–40 %
in asymptomatic carriers [44]. Cytokine-stimulated fibroblasts
are useful for measuring the neopterin and biopterin produc-
tion patterns and GCH-1 activity. After stimulation with
interferon-γ and tumor necrosis factor-α, the concentrations
of neopterin and biopterin were extremely low compared with
those of normal fibroblasts [45]. There were reports that the
abnormal cDNA of abnormal GCH-1 gene produced an en-
zyme protein without activity [44], and that the proportion of
mutant mRNA compared with normal mRNA for GCH-1 was
28 % in the affected patients, and 8 % in asymptomatic carrier
[46].
Imaging Study
DAT is contained in the dopaminergic nerve terminals. DAT
imaging reflects the integrity of nigrostriatal dopaminergic
nerve terminals. DAT binding in the striatum is markedly
decreased in patients with PD and juvenile PD, whereas it is
normal in DRD [15, 33, 47–49]. Fluorodopa PET shows
similar findings in that fluorodopa uptake is markedly de-
creased in PD and JPD, whereas it is normal in DRD
[34–36]. These results show that there is nigral cell loss and
accompanying loss of dopaminergic nerve terminals in PD
and JPD, whereas there is no nigral cell loss and intact dopa-
minergic nerve terminals in DRD. Thus, DAT imaging and
fluorodopa PET are extremely useful in differentiating DRD
from JPD.
Gene Study
Because not all GCH-1 deficient DRD patients have GCH-1
mutations in the gene’s coding region or in the splice sites,
which are detectable by current genomic DNA sequencing of
the GCH-1 gene [50], and because of the high occurrence of
sporadic mutations in this gene [51], DNA testing for the
autosomal dominant DRD is not suitable for routine clinical
practice and must be complemented by enzymatic tests.
Suzuki et al. reported that in 40 % of DRD patients no
mutation was found in the GCH-1 gene [52]. The inability
to detect GCH-1 mutations in apparently typical phenotypes
was also reported in the papers of Hagenah et al. and Zirn et al.
where extensive screening for GCH-1 was done [53, 54].
Mutation of the GCH-1 Gene
GCH-1 is a good example of how the same gene can cause
different phenotypes such as DRD and DRD-plus depending
on the severity of the mutation, which was predicted in the
above section. Hahn et al. classified GCH-1 gene mutations
into the 3 different phenotypes depending on the gene defects:
(1) autosomal dominant hereditary progressive and/or
levodopa-responsive dystonia (AD GCH-1 deficiency - the
prototype of DRD, characterized by childhood-onset dystonia
with sustained clinical responsiveness to low doses of L-
dopa); (2) autosomal recessive GCH-1 deficient HPA (AR
GCH-1 deficient HPA, presenting in early life with a severe
neurologic disorder such as psychomotor retardation, convul-
sions, etc.); and (3) compound heterozygote mutations (inter-
mediate in severity between the above disorders) [55].
Patients with the AD GCH-1 deficiency have a dys-
tonic movement disorder without mental retardation or
convulsions. Biochemically, they have a milder defect in
biogenic amine and BH4 metabolism (based on the
results of cerebrospinal fluid (CSF) studies) than pa-
tients with the recessive form of the disease. With L-
dopa administration, the motor dysfunctions in these
patients dramatically improve. Biochemical studies of
patients with recessive mutations of the GCH-1 gene
have shown severe defects in BH4 metabolism that
correlate with the severity of the neurologic symptoms,
low biogenic amine metabolite levels in the CSF, and
only partial responsiveness to neurotransmitter precur-
sors (L-dopa and 5-hydroxytryptophan) and cofactor
administration [24]. Marked depletion of BH4 in
brainstem serotonin neurons, which have important roles
in postural augmentation and locomotion induces hypo-
tonia and difficulty in locomotive movements or
crawling in infancy [56]. Furthermore, the serotonin
neurons have important roles in the functional develop-
ment of the cortex by modulating synaptogenesis [57].
The changes in the non-nigrostriatal dopaminergic sys-
tem and structural changes exceed the definition of
DRD, thus, making these cases DRD-plus, and indicate
461, Page 4 of 13 Curr Neurol Neurosci Rep (2014) 14:461
that symptoms may not be completely reversed by neu-
rochemical replacement therapy.
Furukawa reported intermediate cases between DRD and
AR GCH-1 deficient HPA [51]. Patient 1 showed a rather
severe motor phenotype of developmental delay and truncal
hypotonia at age 6 months, and lethargy at age 5 years. L-dopa
did not completely reverse her motor disability. Oral BH4 in
Patient 1 provided significant additional benefits, but did not
result in complete resolution of her motor problems. Patient 2
had a more benign developmental motor delay of sitting alone
at 8 months, crawling at 12 months, and walking indepen-
dently at 18 months. Language development was normal even
though he had mild dysarthria. He was able to walk indepen-
dently with braces with 150 mg of L-dopa daily. Both cases
had compound heterozygous mutations in GCH-1, and had
substantially lower BH4 and neopterin levels in the CSF than
that of DRD. Therefore, the severity of the BH4 biosynthetic
defect in the 2 compound heterozygotes described here ap-
pears to be intermediate between that seen in DRD and AR
GCH-1 deficient HPA. The authors state that they are inter-
mediate clinically and biochemically between DRD and AR
GCH-1 deficient HPA disorders. In our scheme, Patient 1 is
regarded as DRD-plus, and Patient 2 may as well be classified
as DRD. It is interesting to note that even though both cases
had compound heterozygous mutations, Patient 1 had frame
shift and missense mutations, whereas patient 2 had 2 mis-
sense mutations.We suspect that the mutation in Patient 1 was
more severe than that in Patient 2, causing a more severe
biochemical deficiency and clinical phenotype. However, the
CSF BH4 levels in these cases were similar. Nevertheless,
they cannot be directly compared because of the different age
at testing and the age-dependent changes in the normal range
[58].
Because the residual enzyme activity will determine the
phenotype, we suspect that the mild form of homozygous or
compound heterozygous mutation in GCH-1 will result in
DRD but not DRD-plus as in Patient 2 from Furukawa et al.
study [24]. A case by Hwu et al. illustrates this point [59]. The
case was a 12-year-old girl with dystonia, diurnal fluctuation,
and a sustained good response to L-dopa. She had a homozy-
gous Arg249Ser mutation, and a normal amount of GCH-1
mRNA but low GCH-1 activity. In transfected eukaryotic
cells, the Arg249Ser mutant protein expression level was
lower than that of the wild-type protein. Therefore, Arg249Ser
was suspected to be a destabilizing mutation. A patient with
typical DRD was reported as a “compound heterozygote with
the AR trait”. The authors reported 2 mutant alleles
Lys224Stop and Pro23Leu in the GCH-1. However, 1 muta-
tion Pro23Leu is believed to be functionally insignificant.
This case is better regarded as DRD with an AD GCH-1
mutation in 1 allele (Lys224Stop) [60]. These cases emphasize
that the severity of mutation and protein dysfunction deter-
mines the clinical phenotype rather than the number of
mutations and the relevance of the uncovered mutation should
be interpreted with care in terms of the clinical presentation.
Mutations of TH
TH enzymatic activity is mainly expressed in the brain and
adrenal medulla. Therefore, measurement of TH enzyme ac-
tivity in blood cells or cultured fibroblasts is not a diagnostic
option. Decreased CSF levels of homovanillic acid (HVA) and
3-methoxy-4-hydroxyphenylglycol (MHPG), together with
normal pterin and CSF tyrosine and 5-Hydroxyindoacetic acid
(5-HIAA) concentrations are the diagnostic hallmarks of iso-
lated TH deficiency. Clinical severity correlates with the bio-
chemical phenotype, probably depending on the nature of the
causative mutations as discussed in GCH-1 [61].
Three phenotypes have been reported: (1) progressive in-
fantile encephalopathy [62, 63], (2) L-Dopa-responsive infan-
tile parkinsonism with a rather good response to L-dopa
therapy, which was limited by the occurrence of dyskinesia
[64], and (3) typical DRD [65–67].
Progressive infantile encephalopathy is dominated by mo-
tor retardation, fluctuating extrapyramidal, and ocular and
vegetative symptoms. Treatment with L-dopa ameliorates
but usually does not normalize symptoms [63]. L-dopa-
responsive infantile parkinsonism is characterized by early
infantile onset severe motor disturbances including parkinson-
ism, myoclonic jerks, and ptosis due to sympathetic denerva-
tion. Parkinsonism is responsive to L-dopa and ptosis to an
ocular instillation of 2.5 % (w/v) phenylephrine [64]. The
above cases belong to DRD-plus in our scheme.
Typical DRD was also described in reports as mentioned
below [65–67]. Two siblings manifested with lower-limb
onset generalized dystonia. Patient 1 showed walking diffi-
culties with increased muscle tone at age 3, and was in a
wheelchair-bound state within 10 years. Patient 2, the younger
brother, also had walking problems due to dystonia, which
made him wheelchair-bound within 7 years. He revealed
developmental delay and panic disorder, probably because
of rhesus incompatibility and from the drug treatment, respec-
tively. They had a compound heterozygous mutation
(Asp498Gly, Ala376Val). Both had a sustained response to
low-dose L-dopa for over 35 years [65]. In another report, 3
patients from 2 families had onset at age 2. At age 5, they were
wheelchair bound. L-dopa normalized motor performance,
and the benefit continued without fluctuation in efficiency
after 30 years [67]. Ludecke et al. reported 2 siblings with
moderate extrapyramidal symptoms with clinical onset in the
first decade and a dramatic positive therapeutic response to
low-dose L-DOPA therapy. Diurnal fluctuations were present.
The genetic defect in exon 11 was Gln381Lys. No biochem-
ical assay was done [66].
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Mutations of SR
SR converts 6-PPH4 to BH4. A defect in SR causes dopamine
deficiency, serotonin deficiency, and neurotoxicity [30]. Pa-
tients with SR deficiency show diurnally fluctuations and
dopa-responsive movement disorders like in typical DRD
cases. However, most patients have additional neurologic
problems, such as developmental delay, hypotonia, oculogyric
crises, and cognitive impairment due to additional serotoner-
gic defects [68–74]. CSF analysis revealed low 5-HIAA and
HVA and high total biopterin, BH2, and sepiapterin.
Neopterin is not significantly different from the reference
range. Decreased SR activity in fibroblasts and genetic study
are helpful in diagnosis [75].
Patients with SR deficiency show clinical heterogeneity
depending on the severity of the genetic and enzymatic defect.
A patient with a homozygous mutation presented with mental
and growth retardation, microcephaly, and spasticity, as well
as dystonia [68]. His SR activity in fibroblasts was under
10 mU/mg (controls, 99~185 mU/mg). On the other hand,
the DRD phenotype was reported in a heterozygous mutation
of SR [69]. The patient was a 26-year-old woman who walked
on tiptoes since childhood. Motor disturbance was the only
manifestation, which showed pronounced fluctuations. L-
dopa was effective but with headaches and nausea. The SR
activity in her fibroblasts was 62mU/mg, which is higher than
that of the previous homozygous case. Haplo-insufficiency of
the sepiapterin reductase gene (SPR) was suggested as the
molecular pathologic mechanism resulting in DRD in the
patient. There is another report showing gene-enzyme-
phenotype correlations, in which Arrabal et al. presented 4
cases of SR deficiency and showed a good correlation be-
tween the severity of the mutations and the severity of the
phenotypes [74]. SR deficiency showed good L-dopa respon-
siveness in general, and received additional benefits from 5-
hydroxytryptophan in cognitive deficit, as well as motor and
sleep symptoms [75].
Mutations of the Dopamine Transporter and Vesicular
Monoamine Transporter 2: Transportopathies
There are 2 important reports showing deficits in the neuro-
transmitter transporting system, not in the biosynthesis of
dopamine [76••, 77••]. The mutations of SLC6A3, a gene
located on 5p15.3, results in DAT deficiency [76••]. Because
the function of DAT is mainly reuptake of dopamine into
presynaptic dopaminergic neurons, DAT deficiency results
in abundant dopamine in the synaptic cleft and overactivation
of D2 autoreceptors leading to decreased dopamine produc-
tion. The clinical feature of DAT deficiency is very similar to
DRD-plus as we proposed. The age of onset is younger than
that of DRD. It shows nonmotor and systemic manifestations,
as well as parkinsonism and dystonia. There are no diurnal
fluctuations in DAT deficiency. L-dopa was only partially
effective. For the diagnosis, DAT imaging is very helpful,
revealing complete loss of DAT binding in the basal ganglia.
Vesicular monoamine transporter 2 (VAMT2) deficiency af-
fects more of the neurotransmitter system, including dopa-
mine, serotonin, epinephrine, and norepinephrine [77••].
Jennifer et al. showed that a mutation in SLC18A2, a gene
encodingVMAT2, causes the defects inmonoamine transport.
This disorder also shared many clinical characteristics with
DRD-plus, although L-dopa was completely ineffective to-
ward parkinsonism and dystonia. The characteristics of DAT
deficiency and VAMT deficiency are presented in Table 1.
Atypical Cases
Our definition of DRD is selective nigrostriatal dopaminergic
deficiency. There could be a long discussion as to what neuro-
logic features can be presented by selective nigrostriatal dopa-
minergic deficiency; however, here we mean only motor fea-
tures. Thus, DRD by our definition allows for parkinsonism
and dystonia only. However, there have been reports of atypical
extranigral phenotypes in “DRD”. We argue that these obser-
vations in DRD are just coincidental and not causal.
Depression was not a frequent observation in DRD. Segawa
even argued that depression could be coincidental because he
only reported 1 depressive person among 28 gene proven pa-
tients from 15 families [26]. However, 2 articles emphasized a
high prevalence of psychiatric manifestations. Hahn et al. de-
scribed 11 mutation cases from among more than 70 members
in the pedigree with a high prevalence of depression (4 of 11)
and anxiety (6 of 11) [55]. However, the authors did not examine
mutation noncarriers in the family to compare with mutation
carriers raising the issue of observation bias and other comorbid
disorders in the family. Of interest is that 4 of the 6 cases with
anxiety had deafness, again raising the suspicion of comorbid
disorders. A study by Hove et al. also highlighted that major
depressive disorder and obsessive-compulsive disorder were
strikingly more frequent than observed in the general population
among mutation carriers in their 3 families with proven GCH-1
deficiency [78]. Patients responded well to serotoninergic med-
ication and to L-dopa substitution. Sleep disorders were present
in 55% of the patients. However, mutation negativemembers of
these families were not examined again raising the issue of
observation bias and other comorbid disorders in the family.
Tic syndrome (TS) was seen in 2 siblings with DRD [79].
Both parents also had tics. Because TS did not show diurnal
fluctuations and no improvement in the tics was observed, the
TS appears to be coincidental.
Even cerebellar dysfunction was described in 2 of 4 genet-
ically confirmed cases [23]. The authors describe horizontal
gaze-evoked nystagmus, limb incoordination, and gait ataxia.
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However, the clinical description of the 4 cases is typical
DRD, and not that of ataxic syndrome. This paper also raised
the issue of a false-positive test for anti-glutamic acid decar-
boxylase antibody (patient 3).
Considerations for Diagnosis
L-Dopa Responsiveness
Based on the pathophysiology of DRD in our proposed def-
inition, it is expected that low dose L-dopa should completely
reverse any symptoms in DRD. However, there are papers on
focal dystonia reported as DRD not showing such a remark-
able improvement [80, 81]. There are also several cases with
proven GCH-1 mutations, showing partial improvement
(from no response to 90 % response) [26]. It could be
conjectured that a prolonged dopamine deficiency state in
the basal ganglia somehow deranged the proper motor circuit
resulting in dystonia, which no longer responds to L-dopa. We
would like to speculate that these focal dystonias that do not
respond completely to L-dopa may not be related to DRD and
that the uncovered genetic defect is just coincidental. We
would like to note that the penetrance of the GCH-1 mutation
is only 30 % supporting that the presence of a mutation does
not guarantee clinical symptoms and a diagnosis of DRD [14],
Table 1 Differential diagnosis of JPD, DRD, DRD-plus, and transportopathy
JPD DRD DRD-plus Transportopathy
DAT deficiency VMAT2 deficiency
Age of onset Childhood~Adolescence Childhood~Adolescence Infancy Infancy Infancy
Symptoms and signs
Motor symptoms
Dystonia +/− + +/− + +
Parkinsonism + +/− +/− + +
Nonmotor symptoms - - + + +
Systemic symptoms - - + + +
Diurnal fluctuation +/− + +/− - -
Laboratory tests
DAT imaging Abnormal Normal N/Aa Markedly abnormal N/Aa
CSF NTs Neopterin: A/T subtypeb A/T subtypeb HVA/5-HIAA: Normal




N/Aa A/T subtypeb A/T subtypeb N/Aa N/Aa
L-dopa responsec
Dose Smalld Small Large Large No response
Response degree Good Marked Partial Partial No responsee
Motor complicationsf Frequentg Absent Presenth Presenth Presenth
a It is predicted to be normal.
b According to subtype. Please refer to Supplement Table 1 for details.
c Dopa agonist is more effective than L-dopa in AADC deficiency, DAT deficiency and VMAT2 deficiency.
d Dose increases with time.
e Responds to dopamine agonists.
fMotor fluctuation and dyskinesias.
gMotor complications occur as a late-complication.
h Dyskinesia may appear early by the administration of L-dopa in a dose-dependent manner.
5-HIAA hydroxyindoleacetic acid, AADC Aromatic L-amino acid decarboxylase, A/TAccording to, DAT dopamine transporter, DRD dopa-responsive
dystonia, HVA homovanillic acid, JPD juvenile Parkinson’s disease, N/A not available, NE norepinephrine, NTs neurotransmitters, VMAT2 vesicular
monoamine transporter 2
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and that L-dopa response is so excellent in the most severely
affected DRD cases after many years of treatment delay [25]
that it is hard to imagine that mild clinical symptoms may be
the only and residual symptoms. In our recent report of 19
cases of GCH-1 mutation positive DRD, only 1 case (Case III:
2 in family D) had residual symptoms with facial grimacing
and upper limb dystonia [82•]. Of interest is that her brother
(case III:1) had isolated torticollis, which did not respond to L-
dopa. His gene test revealed no mutation, which raises the
possibility of a second familial dystonic disorder affecting
Case III:1 and Case III:2. Therefore, it is quite surprising that
Tardic et al. [83•] reported high frequencies of residual motor
signs in patients receiving therapy in 28 % from a literature
review and 39 % from their pilot study group.
There are cases of unusual phenotypes such as torticollis or
camptocormia, which are reported as DRD simply because
they responded well to L-dopa. A case by Gerpen et al. was a
48-year-old man with progressive camptocormia particularly
after exertion [84]. The patient could walk backwards and had
sensory tricks. L-dopa (600 mg/day with carbidopa) provided
consistent benefits for over 5 years. The unusual points in this
patient for DRD are the rather high dose of L-dopa and a rapid
recurrence of symptoms after skippingmedication. No genetic
or biochemical study was done.
There was a very intriguing report about familial torticollis
with good dopa-responsiveness [85]. Genetic testing for GCH-1,
TH, and SRwas negative, and therewas no laboratory evidences
supporting DRD, such as CSF neurotransmitters and its metab-
olites, and enzymatic activities. Recently, the authors reported
that the 3 affected members had compound heterozygous muta-
tions in ATM on chromosome 11 [86•]. Two other patients with
the mutation in the family showed typical presentations of ataxia
telangiectasia. Sanders-Pullman et al. [87] reported primary-
appearing dystonia in Canadian Mennonites who carry muta-
tions in the ATM. L-dopa was not effective in the 3 cases
tested. Therefore, the causal relation between the mutations in
ATM and L-dopa responsiveness (which is the main crux of
the term DRD by our definition) appears to be doubtful.
Mutation-Negative DRD
There were families in which no abnormalities in the gene
were detected in the coding region even though there was a
linkage to 14q or a decrease of CSF neopterin or GCH 1
activity in peripheral mononuclear blood cells. Recently, in 1
of these families, a defect in the mRNA was observed in 1
allele [88]. DYT14 was initially thought to exclude GCH-1,
however, later studies showed a large exon deletion of the
GCH-1 gene [89]. In our own paper in 1998, low CSF
neopterin suggested a low activity of the GCH-I enzyme in
Family C (Patients 6 and 7) and Patient 9 [15]. However, we
failed to find mutations in GCH-1 at the time of the report. A
recent analysis showed that Family C has exon1 P95R
(nt284C > G) and Patient 9 (S4 in Lee et al., 2013) has
Gly203Arg [82•]. In addition, a case by Nagata et al. is a
perfect example of DRD-plus with a GCH-1 mutation
suspected but not found [90]. This 20-year-old woman pre-
sented with motor and mental disturbances since ages 2 and 3,
respectively. CSF neopterin was extremely low; however, a
mutation in GCH-1 was not found. A decrease in serum
neopterin, biopterin, and serotonin suggested a severe defi-
ciency in GCH-1. A further search of GCH-1 and its unknown
cofactor is warranted based on these laboratory findings.
These cases show that genetic study alone has limitations. A
biochemical analysis of the CSF would have led the investi-
gation to focus on individual enzymes in BH4metabolism and
TH based on the neopterin level and other chemical levels.
Coexistence with Degenerative Parkinsonism
There are 4 reported cases of DRD and defective nigrostriatal
dopaminergic integrity, which should not be seen in DRD by
our definition. The first case is a Danish male presenting with
DRD at age 28 but later showed features of young-onset PD
(YOPD) at age 35 by manifesting dyskinesia [91]. A mutation
in GCH-1 (Pro199Ser) and decreased GCH-1 enzyme activity
were found supporting a diagnosis of DRD. However, devel-
opment of dyskinesia and decreased DAT binding are indica-
tive of YOPD. Therefore, this case should be regarded as a
mixture of DRD and YOPD, where YOPD would determine
his clinical course. The second case is a 54-year-old man with
parkinsonism caused by an Arg184His mutation in GCH-1
[92]. Arg184His was the first mutation causing both the AR
and AD phenotypes [92, 93]. Fluctuations and dyskinesia,
which are indicative of PD, developed. Fluorodopa PET was
abnormal, supporting the diagnosis of PD but not DRD.
Therefore, this case should be regarded as a mixture of DRD
and PD, where PD would determine his clinical outcome. The
third case is on a 76-year-old woman with a 19 year history of
parkinsonism [26]. The parkinsonian symptoms had been
improved by small doses of L-dopa. However, dyskinesia
and dementia had developed subsequently. Her brain image
showed an enlarged ventricle and an old stroke lesion. She
became wheelchair-bound at age 80 with a fixed flexor pos-
ture of the upper limbs and severe dystonic hand deformities.
Although her sons showed DRD manifestation with a GCH-1
mutation and she also had a GCH-1 mutation, the diagnosis of
DRD is doubtful in terms of the delayed onset, motor com-
plications, dementia, and abnormalities on the brain scan. The
last case is a 65-year-old woman with mild parkinsonian
features and a complete deletion of the GCH-1 gene on 1
allele [94]. Her [123I] FP-CIT single photon emission comput-
ed tomography (SPECT) showed bilateral asymmetric
putaminal deficit. Although the patient’s symptoms were mild
and responded well to low-dose L-dopa, it was slowly pro-
gressive. It means that the cause of her problems is a
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degenerative disease, not an enzymatic defect. Because the
prognosis will be determined by degenerative parkinsonism, it
will be more reasonable to consider degenerative parkinson-
ism than DRD in these cases even though mutations in the
GCH-1 gene were found in these patients. All these cases
emphasize that detailed biochemical analysis, clinical evalua-
tion, DAT imaging and follow-up are needed to be sure that
the uncovered genetic defect is the sole cause of their
symptoms.
Differential Diagnosis from JPD
The difficulties of differentiating JPD from DRD are well
known, and have been a problem from the outset. Several
early clinical descriptions of DRD later turned out to be JPD
and vice versa [12, 34, 95–97]. It is quite understandable in
that both conditions present as young-onset parkinsonism and
dystonia, have a similar remarkable early good therapeutic
response to L-dopa and a positive family history. Diurnal
fluctuations, even prominent ones, have been a common
finding in JPD. Previous reports of DRD, which were later
shown to be JPD based on a later appearance of motor fluc-
tuations and dyskinesia, demonstrate this difficulty [12,
95–97]. The brain of 1 patient was even reported twice, with
diverse conclusions in 2 separate publications; although the
final diagnosis was JPD [98], the patient was initially reported
as DRD [34].
Because JPD is neurodegenerative condition whereas DRD
is a neurochemical disorder, the long-term clinical course is
different in that JPD requires a substantially larger intake of L-
dopa and will ultimately develop motor fluctuations and
dyskinesias. Because the long-term prognosis is different, an
early differential diagnosis is important and possible. The CSF
neopterin level and gene studies can be helpful. However, a
mild decrease in CSF neopterin is possible even in JPD, and a
gene study can be a false negative. DAT imaging or
Fluorodopa PET will be the best tests to clearly differentiate
the 2 conditions [15, 33–36, 47–49].
Diagnosis of DRD and DRD-Plus
The concepts of DRD and DRD-plus are much closer to their
pathogenesis, and are more practical in diagnosis and treat-
ment. (Table 1 and Supplement Table 1) A good example is a
paper by Clot et al. who reported a molecular genetic study on
patients under the categories of pure DRD or DRD-plus [99].
Their definitions of pure DRD and DRD-plus were the same
as ours even though the authors failed to mention our reports
[15, 16]. Among 57 patients with pure DRD, GCH-1, and
PARK2 defects were proven in 46 (80.7 %) and 1 (1.8 %)
patients, respectively. DAT imaging would have easily select-
ed the patient with PARK2 prior to going through the rigorous
genetic screening. The number of patients with DRD-plus
syndrome was seven. The results of the genetic screening
were as follows: GCH-1 deficiency, 1 case (14.3 %); TH
deficiency, 3 cases (42.9 %); SR deficiency, 2 cases
(28.6 %). These results show that our definition could reflect
genetic causes and is useful in guiding a diagnostic work-up.
If the clinical diagnosis is DRD, then genetic screening of
GCH-1 is the most productive (Fig. 2). If GCH-1 screening is
negative, the CSF neopterin and biopterin levels will guide the
Fig. 2 Diagnostic flow for dopa-
responsive dystonia and related
disorders
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investigation to the individual enzymes in BH4 metabolism
and TH. If the CF neopterin is low, an exhaustive study of
GCH-1 is needed, whereas a normal CSF neopterin level will
necessitate examination of other genes in BH4 metabolism
and TH but not in GCH-1. A similar diagnostic algorithm is
also logical in DRD-plus. DAT imaging will reliably screen
DRD-mimicking JPD. Of note is the recent discovery of DAT
and VMAT deficiency syndromes [76••, 77••]. These rare AR
genetic disorders have DRD-plus features of hypo- and hy-
perkinetic movement disorder and ocular motility problems
with onset in infancy. The DAT deficiency syndrome had
raised ratios of HVA to 5-HIAA in the CSF. DAT imaging
showed a complete loss of DAT activity in the basal nuclei. If
the patient with the characteristics of DRD-plus has no abnor-
malities of the neurotransmitters and metabolites in the CSF,
the diagnosis of that patient could be VMAT2 deficiency
[77••]. VMAT2-deficient patients show abnormal neurotrans-
mitters and metabolites only in the urine.
Wemaintain that all symptoms of DRD should be completely
reversed by small dose of L-dopa. Symptoms of DRD-plus may
not be completely reversed because of more extensive non-
nigrostriatal, nondopaminergic and structural changes. DRD-
plus strongly suggests more severe depletion of BH4 and
extranigral nondopaminergic, especially serotonergic involve-
ment. Thus, a BH4 and serotonin trial will be of value.
Conclusions
Dystonic syndromes with L-dopa responsiveness are very
heterogeneous with various clinical, genetic, and biochemical
features. Our clinically oriented concept and definition of
DRD and DRD-plus will help in understanding the patho-
physiology and clinical features, and will help in guiding the
diagnostic investigation and treatment planning. A genetic
study helps significantly in making the diagnosis. However,
it should be noted that the severity of the mutation and protein
dysfunction regardless of the causative gene determines the
clinical phenotype rather than the presence of mutations, and
the same gene mutation may present as DRD or DRD-plus
depending on the severity of the enzymatic defect. Some
pitfalls in genetic studies such as false-negatives, false-
positives and the presence of comorbid conditions will need
to be considered in terms of clinical presentation.
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